Fig. 6.

Venn diagram representation of results obtained from ELISPOT assay binding assay, and PRED^BALB/c prediction. (A) ELISPOT results with 120 15mer peptides from the envelope of the YF virus with CD8-depleted splenocytes; PRED^BALB/c was used to analyze the 120 15mer peptides from the envelope for the presence of class II (I-A^d and I-E^d) binders; ⁎only the seventeen peptides positive by ELISPOT were analyzed by binding assays for class II molecules, and those showing an IC₅₀ < 1000 nM were considered possible binders. (B) ELISPOT results for the 3 out of 28 15mer peptides from the capsid of the YF virus that were considered positive with CD8-depleted splenocytes; PRED^BALB/c was used to analyze the 28 15mer peptides from the capsid for the presence of class II (I-A^d and I-E^d) binders; all 28 15mers from the capsid were tested in binding assays for class II molecules, and those showing an IC₅₀ < 1000 nM were considered possible binders. (C) ELISPOT results with the 16 15mer peptides from the membrane of the YF virus with CD8-depleted splenocytes; PRED^BALB/c was used to analyze the 16 15mer peptides from the membrane for the presence of class II (I-A^d and I-E^d) binders; all 16 were tested in binding assays for class II molecules, and those showing an IC₅₀ < 1000 nM were considered possible binders. (D) ELISPOT results for the 18 9mers from the envelope of the YF virus tested with CD4-depleted splenocytes; PRED^BALB/c was used to analyze the 18 9mer for the presence of class II (I-A^d and I-E^d) binders; all 9mers were tested in binding assays for class I molecules, and those showing an IC₅₀ < 500 nM were considered possible binders. The intersection represents the number of peptides that were positive in two or three of the approaches.